RecruitingNCT05620329

UNC Pleural Fluid Registry

University of North Carolina Pleural Fluid Registry

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

9,999 participants

Start Date

Jan 24, 2018

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Lung Cancer Lung Infection Malignant Pleural Effusion Empyema

Summary

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a registry study — not a treatment trial — collecting samples and data from patients who have fluid buildup around the lungs (pleural effusion) related to infection or cancer, to help researchers better understand and diagnose these conditions. **You may be eligible if...** - You are 18 or older - You are being treated at UNC (as an inpatient or outpatient) - You have pleural fluid (fluid around the lung) and are scheduled for clinically indicated drainage - Your fluid is associated with a lung infection or cancer **You may NOT be eligible if...** - Your doctor believes draining the fluid would be unsafe due to a concurrent medical condition - You are currently incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

UNC Lingeberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05620329

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations